RE:About Opsen growthbossu wrote: Ten years ago revenues at Opsen were $ 8 462 000 and the cost of sales were
$ 2 740 000 for a gross margin of $ 2 740 000 or 32 % and the bottom line a loss of $ 1 930 000
Last year in 2021 revenues were $ 34 464 000 and the cost of sales $ 15 783 000 for a gross margin of $ 18 681 000 or 54 % and the bottom line a loss of $ 1 129 000
So far this year on 9 months ,revenues were $ 26 271 000 and cost $ 12 846 000 and gross margin of $ 13 425 000 or 51 %.and a loss of $ 7 350 000
Assuming revenues of $ 10 000 000 in the Q4 would give a 2022 revenues of $ 36 271 000 and on a Y/Y or 5,2 % increase revenues but a loss of $ 10 000 000
Increase cost in the sales and marketing have been $ 2 779 000 Y/Y
research and development $ 1 944 000 Y/Y and administrative $ 1 271 000 Y/Y for a total increase of $ 5 004 000 in the last 9 months and those expenses made for growth !
In summary, Opsens growth has been exceptional in the last 10 years from $ 8 462 000 to $ 36 271 000 or 428 % increase and the target to reach $ 100 000 000 in 3 years is a huge step and the company has made extra ''expenses''to reach that goal .
However as I told you on my last post the plant '' as is '' will not be able to generate $ 100 000 000 revenues and big investement will have to be made pretty soon .
Next November Annual Financial report should give us some clues on the company strategies to reach their 3 years goal !
Good luck Monsieur Laflamme you have plenty of work in front of you to reach your target but so far you and your team has delivered a spectacular growth with Opsens
If I'm correct, FDA approval could be any day now? GL